CD8+ T Cells Protect During Vein Graft Disease Development.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

1. Nanomedicine-based strategies for the treatment of vein graft disease.Nature reviews. Cardiology · 2025
   Review
2. CD8Journal of translational medicine · 2024
   Review
3. Regulation of vascular remodeling by immune microenvironment after the establishment of autologous arteriovenous fistula in ESRD patients.Frontiers in immunology · 2024
   Review
4. The Role of Immunomodulation in Vein Graft Remodeling and Failure.Journal of cardiovascular translational research · 2021
   Review
5. The curious case of IL-33 in homeostasis and infection.European journal of immunology · 2021
   Article
6. Distinct subsets of T cells and macrophages impact venous remodeling during arteriovenous fistula maturation.JVS-vascular science · 2020
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as